Product Description
PA5108 Latanoprost FA SR Ocular Implant for Mild-moderate Glaucoma.
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: Intraocular
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: PolyActiva
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, New Zealand
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Glaucoma, Open-Angle
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| LATA CS102 | P1 |
Active, not recruiting |
Glaucoma, Open-Angle |
2024-09-30 |
21% |